Stockreport

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

VYNE Therapeutics Inc.  (VYNE) 
PDF VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025Reported positive fir [Read more]